title: Photodynamic therapy outcomes in a case of macular choroidal neovascularization secondary to Candida endophthalmitis.
abstract: OBJECTIVE
  To evaluate the effects on visual function and choroidal neovascularization (CNV) progression in a case of subretinal CNV due to Candida endophthalmitis treated with a combination of photodynamic therapy (PDT) and drugs.
  
  
  METHODS
  A 28-year-old one-eyed woman with CNV in the right eye came to our observation. The CNV developed as a consequence of Candida endophthalmitis. The CNV was treated with six PDT treatments with verteporfin in association with systemic steroid therapy with prednisone (100 mg/day to reduce) and fluconazole (800 mg/day to reduce). Visual acuity (VA) was assessed in pre-PDT conditions and after six PDT treatments (24 months of follow-up).
  
  
  RESULTS
  Pre-PDT VA was 20/125; after 24 months of follow-up, six PDT re-treatments, and pharmacologic therapy, VA was stabilized at 20/100.
  
  
  CONCLUSIONS
  In our case, associated PDT and drug therapies were safe and useful to maintain VA and to arrest CNV progression in the foveal region after 2 years of follow-up.
authors.affiliation: G.B. Bietti Eye Foundation, IRCCS, Roma, Italy. maxtedeschi@libero.it
authors.forename: M
authors.initials: M
authors.lastname: Tedeschi
authors.forename: M
authors.initials: M
authors.lastname: Varano
authors.forename: D
authors.initials: D
authors.lastname: Schiano Lomoriello
authors.forename: C
authors.initials: C
authors.lastname: Scassa
authors.forename: V
authors.initials: V
authors.lastname: Parisi
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000150:complications / Q000188:drug therapy*; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D005451:Fluorescein Angiography; D016469:Fungemia / Q000150:complications / Q000188:drug therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012163:Retinal Detachment; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D000935:Antifungal Agents; D005938:Glucocorticoids; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D015725:Fluconazole; D011241:Prednisone